⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVO News
Novo-Nordisk A/S
Ivim Health GLP-1 Weight Loss Program: Individualized Dosing, Pricing, and What Consumers Should Know in 2026
globenewswire.com
LLY
NVO
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
globenewswire.com
JUNS
BMBL
NVO
ADOCIA Reports Fourth Quarter 2025 Financial Results and Provides a Business Update
businesswire.com
SNGX
NVO
Solve M.E. Funds GLP-1 and Immune Target Studies to Accelerate ME/CFS and Long Covid Breakthroughs
prnewswire.com
NVO
LLY
Bronstein, Gewirtz & Grossman, LLC Is Investigating Novo Nordisk A/S (NVO) And Encourages Stockholders to Connect
accessnewswire.com
NVO
Letter AI Raises $40M Series B to Bring Deal-Level Intelligence to Revenue Enablement
prnewswire.com
ADBE
NVO
ZIP
CRM
HUBS
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access
prnewswire.com
NVO
Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
globenewswire.com
NVO
Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO
businesswire.com
NVO
Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO
businesswire.com
NVO